FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
FENNEC PHARMACEUTICALS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$10.27+0.29 (+2.91%)
Close on Oct 19, 2026
- Market cap
- $374.14M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
46.5%
16M of 35M shares
Institutional holders
105
25 new, 8 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 19 sales
Net sold $11.90M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3,321,333 | 9.60% | 13G (passive) amendment | Jun 30, 2026 |
| Kam Lawrence | 2,799,959 | 8.20% | 13G (passive) amendment | Dec 31, 2025 |
| Southpoint Capital Advisors LP | 2,744,741 | 8.00% | 13G (passive) amendment | Dec 31, 2025 |
| Rosalind Master Fund L.P. | 2,076,840 | 7.50% | 13G (passive) | Sep 30, 2025 |
| AIGH Capital Management LLC | 1,981,501 | 5.70% | 13G (passive) | Mar 31, 2026 |
| Solas Capital Management, LLC | 1,889,366 | 5.40% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FENC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3,188,001 | 9.09% | $34.27M | +279,800 | 12.73% |
| AIGH Capital Management LLC | 2,486,038 | 7.09% | $26.72M | +504,537 | 1.68% |
| Solas Capital Management, LLC | 1,889,366 | 5.39% | $20.31M | −592,832 | 10.88% |
| BlackRock, Inc. | 1,727,069 | 4.93% | $18.57M | +358,893 | 0.00% |
| AWM Investment Company, Inc. | 1,160,296 | 3.31% | $12.47M | +440,161 | 1.08% |
| Vanguard Capital Management LLC | 839,306 | 2.39% | $9.02M | −57,838 | 0.00% |
| Prospect Capital Advisors, LLC | 497,800 | 1.42% | $5.35M | New | 2.43% |
| State Street Corp | 426,004 | 1.21% | $4.58M | +66,949 | 0.00% |
| Geode Capital Management, LLC | 402,566 | 1.15% | $4.33M | +30,828 | 0.00% |
| Jane Street Group, LLC | 233,877 | 0.67% | $2.51M | New | 0.00% |
| Potomac Capital Management, Inc. | 224,400 | 0.64% | $2.41M | – | 1.65% |
| Morgan Stanley | 221,920 | 0.63% | $2.39M | +10,812 | 0.00% |
| Vanguard Portfolio Management LLC | 199,998 | 0.57% | $2.15M | +31,525 | 0.00% |
| Northern Trust Corp | 167,922 | 0.48% | $1.81M | +15,799 | 0.00% |
| Marshall Wace, Llp | 138,758 | 0.40% | $1.49M | New | 0.00% |
| Renaissance Technologies LLC | 134,200 | 0.38% | $1.44M | New | 0.00% |
| Nuveen, LLC | 131,482 | 0.37% | $1.41M | +70,534 | 0.00% |
| Trexquant Investment LP | 119,122 | 0.34% | $1.28M | +67,253 | 0.01% |
| CenterBook Partners LP | 118,582 | 0.34% | $1.27M | New | 0.06% |
| Lion Point Capital, LP | 112,434 | 0.32% | $1.21M | – | 5.78% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 105 | 16M | 46.5% | 25 / 44 | 18 / 8 | 4M | 4M |
| Q1 2026 | 90 | 16M | 46.2% | 16 / 38 | 18 / 20 | 3M | 1M |
| Q4 2025 | 96 | 16M | 44.3% | 20 / 26 | 24 / 8 | 4M | 2M |
| Q3 2025 | 84 | 14M | 39.6% | 11 / 27 | 24 / 5 | 1M | 1M |
| Q2 2025 | 78 | 14M | 38.8% | 16 / 25 | 24 / 6 | 1M | 1M |
| Q1 2025 | 68 | 13M | 38.2% | 9 / 21 | 20 / 3 | 1M | 1M |
| Q4 2024 | 64 | 16M | 45.8% | 13 / 25 | 14 / 12 | 2M | 1M |
| Q3 2024 | 63 | 15M | 42.6% | 8 / 26 | 15 / 8 | 2M | 0M |
| Q2 2024 | 64 | 14M | 41.0% | 17 / 25 | 12 / 17 | 1M | 1M |
| Q1 2024 | 65 | 15M | 41.8% | 14 / 25 | 17 / 5 | 2M | 2M |
| Q4 2023 | 56 | 15M | 43.1% | 7 / 22 | 14 / 6 | 2M | 1M |
| Q3 2023 | 55 | 14M | 40.8% | 3 / 17 | 16 / 4 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of FENC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 815,192 | 2.32% | $8.76M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 750,369 | 2.14% | $8.07M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 316,471 | 0.90% | $3.03M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 266,715 | 0.76% | $2.87M | 0.02% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 149,156 | 0.43% | $1.48M | 0.01% | May 31, 2026 |
| Ultra-Small Company Fund | 108,005 | 0.31% | $1.16M | 1.18% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 97,115 | 0.28% | $1.04M | 0.07% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 85,124 | 0.24% | $915.08K | 0.00% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 70,504 | 0.20% | $674.72K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 50,481 | 0.14% | $542.67K | 0.01% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 33,813 | 0.10% | $323.59K | 0.01% | Jul 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 33,380 | 0.10% | $358.84K | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Growth Index Fund | 27,211 | 0.08% | $292.52K | 0.02% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 19,587 | 0.06% | $194.50K | 0.00% | May 31, 2026 |
| Invesco Russell 2000 Dynamic Multifactor ETF | 18,228 | 0.05% | $181.00K | 0.06% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jeffrey S. Hackman | Chief Executive Officer, Director | 66,302 | 0.19% | Aug 31, 2026 |
| Christiana Marie Cioffi | Chief Strategy Officer | 24,644 | 0.07% | Aug 31, 2026 |
| Pierre Sargis Sayad | Chief Medical Officer | 9,519 | 0.03% | Aug 31, 2026 |
| Terry L. Evans | Chief Commercial Officer | 21,519 | 0.06% | Aug 31, 2026 |
| Robert Andrade | CHIEF FINANCIAL OFFICER | 241,306 | 0.69% | Aug 31, 2026 |
| Marco Maria Brughera | Director | 0 | – | Sep 16, 2026 |
| Jodi A. Cook | Director | – | – | Jun 10, 2026 |
| Khalid Islam | Director | 133,333 | 0.38% | Jun 10, 2026 |
| Chris A. Rallis | Director | 63,077 | 0.18% | Jun 10, 2026 |
| Rosty Raykov | – | 124,411 | 0.35% | Sep 1, 2026 |
| Capital Advisors LLC Southpoint | 10% owner | 3,744,741 | 10.68% | Dec 29, 2025 |
| Southpoint GP, LP | 10% owner | 4,077,214 | 11.63% | Dec 29, 2025 |
| Southpoint GP, LLC | 10% owner | 3,764,082 | 10.73% | Dec 29, 2025 |
| Capital Advisors LP Southpoint | 10% owner | 2,744,741 | 7.83% | Dec 29, 2025 |
| John Smith Clark II | 10% owner | 41,504,000 | 118.36% | Dec 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marco Maria Brughera Director | Sep 15, 2026 | Sale(10b5-1 plan) | −15,545 | $10.29 | $159.96K | 0 |
| Marco Maria Brughera Director | Sep 15, 2026 | Option exercise | +15,545 | $2.11 | $32.80K | 15,545 |
| Rosty Raykov – | Sep 1, 2026 | Sale(10b5-1 plan) | −10,000 | $12.11 | $121.10K | 124,411 |
| Rosty Raykov – | Aug 31, 2026 | Award | +2,778 | – | – | 134,411 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Aug 31, 2026 | Award | +1,159 | – | – | 66,302 |
| Terry L. Evans Chief Commercial Officer | Aug 31, 2026 | Award | +168 | – | – | 21,519 |
| Pierre Sargis Sayad Chief Medical Officer | Aug 31, 2026 | Sale | −12,000 | $12.18 | $146.16K | 9,519 |
| Pierre Sargis Sayad Chief Medical Officer | Aug 31, 2026 | Award | +168 | – | – | 21,519 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Aug 31, 2026 | Award | +1,703 | – | – | 241,306 |
| Christiana Marie Cioffi Chief Strategy Officer | Aug 31, 2026 | Award | +156 | – | – | 24,644 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Aug 28, 2026 | Option exercise | +21,928 | $5.10 | $111.83K | 239,603 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Aug 27, 2026 | Sale(10b5-1 plan) | −75,000 | $11.78 | $883.50K | 217,675 |
| Rosty Raykov – | Aug 3, 2026 | Sale(10b5-1 plan) | −10,000 | $9.58 | $95.80K | 131,633 |
| Pierre Sargis Sayad Chief Medical Officer | Jul 31, 2026 | Award | +168 | – | – | 21,351 |
| Rosty Raykov – | Jul 31, 2026 | Award | +2,778 | – | – | 141,633 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Jul 31, 2026 | Award | +1,159 | – | – | 65,143 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Jul 31, 2026 | Award | +1,703 | – | – | 292,675 |
| Christiana Marie Cioffi Chief Strategy Officer | Jul 31, 2026 | Award | +156 | – | – | 24,488 |
| Terry L. Evans Chief Commercial Officer | Jul 31, 2026 | Award | +168 | – | – | 21,351 |
| Rosty Raykov – | Jul 1, 2026 | Sale(10b5-1 plan) | −9,599 | $10.41 | $99.93K | 138,855 |
| Rosty Raykov – | Jul 1, 2026 | Option exercise | +15,597 | $2.45 | $38.21K | 148,454 |
| Rosty Raykov – | Jul 1, 2026 | Award | +2,778 | – | – | 132,857 |
| Pierre Sargis Sayad Chief Medical Officer | Jun 30, 2026 | Award | +168 | – | – | 21,183 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Jun 30, 2026 | Award | +1,703 | – | – | 290,972 |
| Terry L. Evans Chief Commercial Officer | Jun 30, 2026 | Award | +168 | – | – | 21,183 |
| Christiana Marie Cioffi Chief Strategy Officer | Jun 30, 2026 | Award | +156 | – | – | 24,332 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Jun 30, 2026 | Award | +1,159 | – | – | 63,984 |
| Rosty Raykov Director | Jun 1, 2026 | Option exercise | +15,597 | $2.45 | $38.21K | 139,826 |
| Rosty Raykov Director | Jun 1, 2026 | Sale(10b5-1 plan) | −9,747 | $9.62 | $93.77K | 130,079 |
| Rosty Raykov Director | May 31, 2026 | Award | +2,778 | – | – | 124,229 |
| Robert Andrade CHIEF FINANCIAL OFFICER | May 31, 2026 | Award | +1,703 | – | – | 289,269 |
| Christiana Marie Cioffi Chief Strategy Officer | May 31, 2026 | Award | +156 | – | – | 24,176 |
| Terry L. Evans Chief Commercial Officer | May 31, 2026 | Award | +168 | – | – | 21,015 |
| Jeffrey S. Hackman Chief Executive Officer, Director | May 31, 2026 | Award | +1,159 | – | – | 62,825 |
| Pierre Sargis Sayad Chief Medical Officer | May 31, 2026 | Award | +168 | – | – | 21,015 |
| Chris A. Rallis Director | May 11, 2026 | Sale(10b5-1 plan) | −8,346 | $7.04 | $58.76K | 63,077 |
| Chris A. Rallis Director | May 11, 2026 | Option exercise | +14,344 | $2.44 | $35.00K | 71,423 |
| Rosty Raykov Director | May 1, 2026 | Option exercise | +15,598 | $2.45 | $38.22K | 132,232 |
| Rosty Raykov Director | May 1, 2026 | Sale(10b5-1 plan) | −10,781 | $6.47 | $69.75K | 121,451 |
| Pierre Sargis Sayad Chief Medical Officer | Apr 30, 2026 | Option exercise | +168 | – | – | 20,847 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Apr 30, 2026 | Option exercise | +1,159 | – | – | 61,666 |
| Terry L. Evans Chief Commercial Officer | Apr 30, 2026 | Option exercise | +168 | – | – | 20,847 |
| Rosty Raykov Director | Apr 30, 2026 | Option exercise | +2,778 | – | – | 116,634 |
| Christiana Marie Cioffi Chief Strategy Officer | Apr 30, 2026 | Option exercise | +155 | – | – | 24,020 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Apr 30, 2026 | Option exercise | +1,703 | – | – | 287,566 |
| Rosty Raykov Director | Apr 1, 2026 | Option exercise | +15,598 | $2.45 | $38.22K | 124,802 |
| Rosty Raykov Director | Apr 1, 2026 | Sale(10b5-1 plan) | −10,946 | $6.31 | $69.07K | 113,856 |
| Christiana Marie Cioffi Chief Strategy Officer | Mar 31, 2026 | Option exercise | +17,106 | – | – | 21,806 |
| Christiana Marie Cioffi Chief Strategy Officer | Mar 31, 2026 | Option exercise | +158 | – | – | 21,964 |
| Terry L. Evans Chief Commercial Officer | Mar 31, 2026 | Option exercise | +171 | – | – | 18,627 |
| Terry L. Evans Chief Commercial Officer | Mar 31, 2026 | Option exercise | +18,456 | – | – | 18,456 |
| Pierre Sargis Sayad Chief Medical Officer | Mar 31, 2026 | Option exercise | +171 | – | – | 18,627 |
| Pierre Sargis Sayad Chief Medical Officer | Mar 31, 2026 | Option exercise | +18,456 | – | – | 18,456 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Mar 31, 2026 | Option exercise | +16,695 | – | – | 45,405 |
| Jeffrey S. Hackman Chief Executive Officer, Director | Mar 31, 2026 | Option exercise | +1,159 | – | – | 46,564 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Mar 31, 2026 | Option exercise | +14,724 | – | – | 271,380 |
| Robert Andrade CHIEF FINANCIAL OFFICER | Mar 31, 2026 | Option exercise | +2,213 | – | – | 273,593 |
| Rosty Raykov Director | Mar 31, 2026 | Award | +5,208 | – | – | 109,204 |
| Christiana Marie Cioffi Chief Strategy Officer | Mar 28, 2026 | Option exercise | +1,901 | – | – | 23,865 |
| Terry L. Evans Chief Commercial Officer | Mar 28, 2026 | Option exercise | +2,052 | – | – | 20,679 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Brughera Marco Director | Sep 15, 2026 | 15,545 | $160.07K | Sep 15, 2026 | Stock Option Exercise |
| Raykov Rostislav Former Director | Sep 1, 2026 | 10,000 | $121.18K | Sep 1, 2026 | Restricted Stock |
| S. Sayad Pierre Officer | Aug 31, 2026 | 12,000 | $146.17K | Aug 31, 2026 | Performance Shares |
| Andrade Robert Officer | Aug 27, 2026 | 75,000 | $883.90K | Aug 27, 2026 | Exercised Shares |
| Raykov Rostislav Former Director | Aug 3, 2026 | 10,000 | $95.84K | Aug 3, 2026 | Restricted Stock |
| Raykov Rostislav Director | Jul 1, 2026 | 9,599 | $99.99K | Jul 1, 2026 | Stock Option Exercise |
| Raykov Rostislav Director | Jun 1, 2026 | 9,747 | $93.81K | Jun 1, 2026 | Stock Option Exercise |
| A. Rallis Chris Director | May 11, 2026 | 8,346 | $58.83K | May 11, 2026 | Stock Option Exercise |
| Raykov Rostislav Director | May 1, 2026 | 10,781 | $69.76K | May 1, 2026 | Stock Option Exercise |
| Raykov Rostislav Director | Apr 1, 2026 | 10,946 | $69.07K | Apr 1, 2026 | Stock Option Exercise |
| Raykov Rostislav Director | Mar 2, 2026 | 10,079 | $84.35K | Mar 2, 2026 | Stock Option Exercise |
| Raykov Rostislav Director | Feb 2, 2026 | 10,349 | $80.34K | Feb 2, 2026 | Stock Option Exercise |
| Raykov Rostislav Director | Jan 2, 2026 | 10,312 | $78.47K | Jan 2, 2026 | Stock Option Exercise |
| Raykov Rostislav Director | Dec 5, 2025 | 10,000 | $75.44K | Dec 5, 2025 | Restricted Stock |
| Raykov Rostislav Director | Nov 5, 2025 | 10,000 | $81.08K | Nov 5, 2025 | Restricted Stock |